Wireless NFC Implant Delivers Chemotherapy Deep Into Tumors With Four-Fold Improved Efficiency
Key Insights
Researchers from Seoul National University and Korean institutions developed a wireless implantable drug delivery system that uses Near-Field Communication (NFC) technology to deliver anticancer drugs (search) deep into solid tumors (search) without harming healthy tissue.
The Dual-Phoretic Wireless Drug Delivery System (DPw-DDS) achieved over four times greater drug delivery efficiency than standard injection methods and reduced tumor volume by more than 50% within five weeks in vivo experiments.
The system integrates electrophoresis and iontophoresis mechanisms in a compact subcutaneous implant, eliminating the need for external wiring or batteries while supporting various drug types including nanomedicines (search) and mRNA (search) therapeutics.
A multidisciplinary research team from Seoul National University, the Korea Institute of Science and Technology (search) (KIST), Kwangwoon University (search), and Gyeongsang National University has developed a breakthrough wireless implantable drug delivery system that enables anticancer drugs (search) to penetrate deep into solid tumors (search) without harming surrounding healthy tissue. The findings, published in Science Advances, represent a significant advancement in addressing one of chemotherapy (search)'s most persistent challenges.
Addressing the Solid Tumor Penetration Challenge
Solid tumors (search) have long resisted conventional drug therapies due to their dense cellular architecture and elevated interstitial pressure. Anticancer drugs (search) delivered via injection often remain trapped in the outer regions of a tumor, requiring high systemic doses to achieve therapeutic effect. This approach increases the risk of severe side effects such as immune suppression, gastrointestinal toxicity, and the rapid emergence of drug resistance.
Dual-Mechanism Wireless Technology
To solve this challenge, the research team developed the Dual-Phoretic Wireless Drug Delivery System (DPw-DDS)—a fully implantable device that uses two ionic transport mechanisms. First, electrophoresis enables on-demand, pulsatile, and quantitative release of drugs using an ion-selective diode. Second, iontophoresis employs electric fields to push those drugs deep into tumor tissue.
The system is wirelessly powered using Near-Field Communication (NFC), allowing fully untethered operation without the need for external wiring or batteries. All essential drug delivery steps—storage, release, penetration, and dosing—are integrated into a single, compact device designed for subcutaneous implantation.
Significant Therapeutic Improvements
In vivo experiments demonstrated that the system achieved over four times greater drug delivery efficiency than standard injection methods and reduced tumor volume by more than 50% within five weeks. Throughout the study, no damage to major organs or surrounding healthy tissue was observed, highlighting the system's biocompatibility and safety.
"This system integrates controlled release and deep tissue targeting in a compact wireless form. It could reshape how we treat not only cancer (search) but a wide range of diseases requiring precise and sustained drug delivery," said Prof. Seung-Kyun Kang from Seoul National University.
Broad Therapeutic Applications
Because the system does not require reformulating drugs, it can be readily applied to existing therapeutics, potentially reducing the cost and time associated with drug development. The platform also supports a wide range of drug types—including nanomedicines (search), protein therapeutics, and mRNA (search)—making it suitable for treating cancer (search), chronic inflammation (search), and other precision medicine targets.
Future Development and Clinical Translation
Looking ahead, the team aims to extend the platform to biodegradable, non-retrievable implants, eliminating the need for surgical removal and paving the way for long-term, low-burden treatment options. The integration of physical drug delivery principles with wireless bioelectronics marks a major step toward next-generation implantable therapies.
"This platform provides a practical solution for improving therapeutic efficacy while minimizing side effects. We are actively working toward clinical translation and commercialization," added Dr. Hyojin Lee from the Korea Institute of Science and Technology (search).